The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 06, 2026
Filed:
Mar. 10, 2021
Applicants:
Eubulus Biotherapeutics (Hong Kong) Limited, Hong Kong, HK;
Sheldon Cao, San Diego, CA (US);
Xiaolei Wang, Jiaxing, CN;
Inventors:
Sheldon Cao, San Diego, CA (US);
Xiaolei Wang, Jiaxing, CN;
Assignees:
EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED, Hong Kong, HK;
Other;
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07C 237/22 (2006.01); A61K 31/167 (2006.01); A61K 31/18 (2006.01); A61K 31/245 (2006.01); A61K 31/277 (2006.01); A61K 31/337 (2006.01); A61K 31/351 (2006.01); A61K 31/36 (2006.01); A61K 31/365 (2006.01); A61K 31/381 (2006.01); A61K 31/404 (2006.01); A61K 31/4155 (2006.01); A61K 31/416 (2006.01); A61K 31/4184 (2006.01); A61K 31/4245 (2006.01); A61K 31/428 (2006.01); A61K 31/433 (2006.01); A61K 31/437 (2006.01); A61K 31/44 (2006.01); A61K 31/4412 (2006.01); A61K 31/5377 (2006.01); A61P 35/00 (2006.01); C07C 255/60 (2006.01); C07C 311/08 (2006.01); C07C 311/16 (2006.01); C07C 317/40 (2006.01); C07D 213/56 (2006.01); C07D 213/64 (2006.01); C07D 213/89 (2006.01); C07D 231/56 (2006.01); C07D 249/18 (2006.01); C07D 271/12 (2006.01); C07D 277/64 (2006.01); C07D 285/14 (2006.01); C07D 303/04 (2006.01); C07D 305/06 (2006.01); C07D 309/06 (2006.01); C07D 309/14 (2006.01); C07D 317/66 (2006.01); C07D 333/24 (2006.01); C07D 405/12 (2006.01); C07D 407/12 (2006.01);
U.S. Cl.
CPC ...
C07C 237/22 (2013.01); A61K 31/167 (2013.01); A61K 31/18 (2013.01); A61K 31/245 (2013.01); A61K 31/277 (2013.01); A61K 31/337 (2013.01); A61K 31/351 (2013.01); A61K 31/36 (2013.01); A61K 31/365 (2013.01); A61K 31/381 (2013.01); A61K 31/404 (2013.01); A61K 31/4155 (2013.01); A61K 31/416 (2013.01); A61K 31/4184 (2013.01); A61K 31/4245 (2013.01); A61K 31/428 (2013.01); A61K 31/433 (2013.01); A61K 31/437 (2013.01); A61K 31/44 (2013.01); A61K 31/4412 (2013.01); A61K 31/5377 (2013.01); A61P 35/00 (2018.01); C07C 255/60 (2013.01); C07C 311/08 (2013.01); C07C 311/16 (2013.01); C07C 317/40 (2013.01); C07D 213/56 (2013.01); C07D 213/64 (2013.01); C07D 213/89 (2013.01); C07D 231/56 (2013.01); C07D 249/18 (2013.01); C07D 271/12 (2013.01); C07D 277/64 (2013.01); C07D 285/14 (2013.01); C07D 303/04 (2013.01); C07D 305/06 (2013.01); C07D 309/06 (2013.01); C07D 309/14 (2013.01); C07D 317/66 (2013.01); C07D 333/24 (2013.01); C07D 405/12 (2013.01); C07D 407/12 (2013.01); C07C 2601/02 (2017.05); C07C 2601/14 (2017.05);
Abstract
Provided herein are GPX4 inhibitors, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a GPX4-mediated disorder, disease, or condition.